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Introduction
Alzheimer’s Disease (AD) and Creutzfeldt-Jacob Disease (CJD) 
are two disorders characterized by their neurodegenerative 
symptoms. These ailments are both considered forms of demen-
tia consisting of phenotypes portraying a patient’s loss of mem-
ory, mood irregularities, paranoia, and several other neurological 
symptoms. Physiologically, AD is characterized by its Amyloid-β 
and Tau protein plaques while CJD is characterized by its prev-
alence of misfolded prion proteins throughout the brain.  Albeit 
these two diseases are believed to have different modes of phys-
iological symptoms, they share many similarities with each other 
and other neurodegenerative disorders causing many scientists 
to theorize a possible correlation between their mechanisms. It is 
partly due to these similarities that physicians often misdiagnose 
various dementia relating disorders as either CJD or AD.  In a 
study of 304 autopsies that showed no prion disease prevalence, 
71 (23%) of the patients had Sporadic CJD (a variant form of CJD 
characterized by unknown cause) as a possible diagnosis in their 
medical records (Chitravas, et al., 2011). Another study showed 
that “between 12% and 23% of patients diagnosed with AD do 
not have sufficient AD pathology at autopsy to account for the 
presence of dementia (“misdiagnosed”) (Gaugler, et al., 2013).” 
Due to the vast likeness between many dementias, there has not 
been a definitive noninvasive procedure to precisely diagnose dis-
orders such as CJD and AD (Mayo Clinic Staff, 2014). 
Although AD and CJD share similarities, their prevalence in 
American society is far dissimilar. AD is the 6th leading cause 
of death with an estimated 5.5 million people over the age of 
65 who are afflicted with this neurodegenerative disorder in the 
United States (Sultana, et al., 2013). CJD on the other hand, dis-
plays a prevalence of a mere 4.6 cases per million people over the 
age of 60 ( Centers for Disease Control and Prevention , 2014). 
This is far fewer than the thousands of people who are diagnosed 
each year with AD. 
Despite the rarity of CJD, numerous research endeavors have 
been conducted in understanding this prion disease. One expla-
nation for this attention is due to the unique properties of a 
prion; a protein which acts as an infectious pathogen misfolding 
other proteins into additional prions (Wadsworth, et al., 2008). 
What is more surprising is that prions have been found in pa-
tients diagnosed with AD (Armstrong, et al., 2005). This would 
further suggest a possible correlation between pathogenic mech-
anisms of AD and CJD. Today various treatments for AD and CJD 
are currently in clinical trials to try to treat these incurable dis-
eases. If there is a correlation between pathological mechanisms, 
further research into one of these neurodegenerative disorders 
can help scientists better understand and treat the other. 
The purpose of this research article will be to define and explain 
the physical and physiological symptoms and mechanisms of AD 
and CJD, suggest possible correlations between the two, discuss 
current treatments, and lastly, the different forms of possible 
treatments will be compared to postulate a possible venue to 
determine if they would be effective to treat the other illness. 
Methods
Several online databases were used such as: Google Scholar, 
PubMed, and Jstor which were accessed through Touro College’s 
online library. Additional references were gleaned from papers 
found in these databases
Discussion
CJD Pathophysiology
CJD is quite unique due to its pathophysiological mechanism. 
While most infectious diseases are viral or bacterial based, CJD 
uses a prion to spread its illness. In actuality, every individual con-
tains Prion Proteins (PrPc) which are believed to be necessary 
for normal synaptic function (Collinge, et al., 1994). It is when 
this human-coded PrPc is post-translated and converted into 
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an abnormal isoform (PrPsc) that it starts to exhibit patholog-
ical tendencies. Data suggests that this abnormal protein is the 
main, if not the solitary, component of the transmissible disease 
(Wadsworth, et al., 2008). Once the PrPsc comes into contact 
with a normal PrPc, it causes a transmutation of residue 129 
turning it into a pathological agent.  This replaces the amino acid 
by residue 129 on the protein into either valine or methionine. 
Whereas many scientists agree that the prion protein is the main 
constituent of CJD, there is debate over the validity of this claim. 
Manuelidis, et al (2007), argue that the abnormal PrPsc form of 
the prion protein is a result, not the cause, of CJD. They claim 
that a 25 nm virus is the cause of the abnormal prion isoform. 
They discredit the long accepted hypothesis, that prions are the 
sole pathological constituents of CJD, for several reasons. Studies 
show, “high PrP-expressing transgenic brains, as well as abnormal 
recombinant PrPs, have failed to show significant or reproducible 
infectivity”. Additionally, the authors claim that after several de-
cades of research, scientists found no “infectious conformation” 
of PrPsc. Furthermore, sheep with scrapie showed signs of these 
25 nm viruses while uninfected controls showed no prevalence 
of these particles. These facts caused many researches to share 
doubt on the prion-only hypothesis.
Another theory with tangible evidence suggests a different mode 
of pathological mechanism. Several studies suggest that non-pro-
teinaceous cofactors are needed to facilitate the infectious prop-
erties of PrPsc, hypothesizing that prions work via multiple com-
ponents in order to function (Deleault, et al., 2012). While there 
are studies that show that purified PrPcs which were folded 
chemically into amyloid fibrils showed little infectivity, a combina-
tion of PrPc, liver RNA, and synthetic 1-palmitoyl-2-oleoyl-phos-
phatidylglycerol (POPG) lipid molecules facilitated the produc-
tion of authentic infectious prions. The contrasts between the 
infectivity of PrPc obtained from amyloid fibrils and from PrPc 
combined with lipids and RNA support this theory (see figure 
1). However, further study should be conducted to determine 
whether the cofactors are required for pathology or are merely 
a catalyst for a slow progressive disorder (Supattapone, 2010). 
These experiments cast doubt on the viral hypothesis of prion 
disease. If viruses were the cause of prion pathology, why were 
scientists able to reproduce CJD symptoms with only PrPc and 
various cofactors?
There are several ways for an individual to contract CJD. Factors 
include ingestion of prion-infected tissue, contamination during a 
procedure (most commonly a contaminated tissue transplant or 
equipment), inheritance of a mutation in the PrPc gene (PRNP), 
or sporadically (no apparent cause). When tissue infected with 
abnormal prions is ingested, such as meat from a cow infected 
with Bovine Spongiform Encephalopathy (BSE, also known as Mad 
Cow Disease), a variant form of CJD is contracted named vari-
ant CJD (vCJD). Contamination via a procedure causes a form 
of CJD termed Iatrogenic CJD while a genetic mutation that is 
inherited is called Genetic CJD. CJD that is acquired sporadically 
is referred to as Sporadic CJD (sCJD) (Wadsworth, et al., 2008). 
According to Wadsworth et al (2008), approximately 85% of cases 
with CJD occur as the sporadic variant (sCJD) while 15% are as-
sociated with a pathogenic mutation in the PRNP gene (Genetic 
CJD). Wadsworth further explains that the rare iatrogenic form 
of CJD occurs most frequently due to the transmission of prions 
via contaminated growth hormones from cadavers or by imple-
mentation of contaminated dura mater grafts. Additionally, it has 
been speculated that iatrogenic CJD can be transmitted via blood 
transfusions although it is extremely rare (Ricketts, et al., 1997). 
Prion disease prevalence has been tied to vCJD in the United 
Kingdom by the consumption of cattle with BSE. Another unique 
variant of CJD, named Kuru, is found in the Eastern Highlands of 
Papua New Guinea where members of the community would 
feast on the deceased relatives as a sign of respect and grief. From 
the community in Papua, scientist discovered that the incubation 
period of individuals infected with PrPsc could exceed 50 years 

















Extra ingredients: Two different biochemical protocols yield recombinant PrPc 
with different infectivity. (Left) Minimally infectious amyloid fibrils are formed 
by incubating recombinant PrPc with chemical denaturants� (Right) Mixing 
recombinant PrPc with phospholipid and RNA produces highly infectious prions� 
(Supattapone, 2010)
        
Figure 1
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Individuals with CJD often exhibit phenotypical signs of demen-
tia and various other neurodegenerative symptoms. The pri-
mary indication of CJD is the observation of sponge-like holes 
in a person’s brain giving the appearance of a sponge; for this 
reason, many scientists refer to prion diseases as transmissible 
spongiform encephalopathies (TSEs). Additionally, patients have 
been known to portray feelings of anxiety, depression as well 
difficulties of cognition such as impaired thinking, memory loss, 
personality changes, insomnia and difficulty speaking. Blurred vi-
sion, difficulty swallowing and sudden jerky movements are also 
typical signs of CJD. As the progression of the illness takes its 
course, cognitive phenotypical symptoms worsen. A majority of 
individuals lapse into a coma and eventually die due to cardiac 
arrest, respiratory failure, or an infectious pathogen. The dura-
tion of duress is typically 7 months for classical CJD and 12-14 
months for variant CJD; however, patients have been known to 
live up to 2 years after diagnosis (Mayo Clinic Staff, 2012).
Currently, the only way to verify the diagnosis of CJD is via an 
autopsy to confirm the presence of PrPsc plaques and to observe 
the formation of spongy-like holes and structures within the pa-
tient’s brain; however, doctors can accurately identify this disease 
via several diagnostics. First, a physician might asses the patient 
to determine if he/she portrays any of the symptoms of CJD. 
Additionally, doctors may administer an Electroencephalogram 
(EEG) to measure the individual’s brain’s activity. People with 
CJD typically portray an abnormal pattern. Magnetic resonance 
imaging (MRI) may be used to produce a high resolution image 
of a person’s brain in order to determine a signs of abnormal-
ity. Another known method of testing is a spinal tap where a 
physician withdraws a small amount of cerebral spinal fluid that 
surrounds an individual’s brain and spinal cord. The presence of 
several proteins in the CSF may be an indication of illness (Mayo 
Clinic Staff, 2012). A simple blood test to detect trace amounts 
of PrPsc may be an additional venue to test for CJD, but fur-
ther testing is needed to determine if this is a viable method of 
diagnosis (Castilla, Saa, & Soto, 2005). Furthermore, in a study 
conducted by Moda et al (2014), 13 out of 14 patients with vCJD 
showed signs of PrPsc in their urine samples suggesting a future 
possible diagnostic for vCJD.
AD Pathophysiology 
AD is a form of dementia characterized by the formation of 
Amyloid-β protein (Aβ) plaques or the hyperphosphorylation of 
Tau proteins along with neuron degradation in the brain. This is 
accompanied with numerous cognitive relating symptoms. While 
the symptoms of AD are well documented, there is much debate 
over the exact mechanism in which the disease carriers out its 
pathology. 
One suggested mechanism is through the formation of Amyloid-β 
proteins which in turn form amyloid-β plaques. The Aβ is formed 
from a far larger protein called the β-Amyloid Protein Precursor 
(APP). The cleavage to the Aβ form is catalyzed by the enzyme 
β-CITE APP cleaving enzyme-1 (BACE1) (Small & Cappai, 2006). It 
is believed that when there is an overproduction of Aβ, either via 
a faulty Aβ production mechanism or a failure of the body’s clear-
ance of the protein, Amyloid plaques are formed (Verkhratsky, et 
al., 2014). These aggregations of Aβ are believed to be toxic and 
are the main cause of AD. The conclusion that Aβ is involved with 
the pathogenesis of AD is strongly supported by an experiment 
involving APP transgenic mice. These mice contained human APP 
and when induced with an amyloid disease, showed very simi-
lar pathophysiological symptoms as AD. However, within recent 
years, studies have shown that Aβ plaques are not the most toxic 
form of Aβ. Experiments have shown that a low molecular weight 
diffusable form (non-plaque forming) of Aβ is more toxic. This 
would explain why in APP transgenic mice, abnormal cognitive 
symptoms are seen before Aβ plaque formation (Small & Cappai, 
2006). 
Another well-known hypothesis to the pathological mechanism 
of AD is the formation of toxic hyperphosphorylated tau proteins. 
Normal or dephosphorylated microtubule-associated protein 
(MAP) tau aid in the assembly and stability of microtubule net-
works in neurons. If an abnormality in the MAP tau arises, there 
are two other MAPs (MAP1A/B and MAP2) that can compensate; 
however, when the dephosphorylated tau turns into the hyper-
phosphorylated form, it turns toxic. This pathological form of tau 
sequesters normal tau (MAP1A/B and MAP2) while inhibiting 
and disrupting microtubule structure. The neuron that has been 
afflicted with this pathogenic MAP tries to dispose of the toxic 
substance by synthesizing additional normal tau and by turning 
the hyperphosphorylated form into an inert polymer. Eventually, 
this afflicted neuron begins to degenerate at a progressively slow 
pace. Aggregation of this abnormally hyperphophorylated tau has 
been linked to dementia and neurofibrillary degradation. This 
abnormal MAP tau appears to be the main contributor to tau 
pathologies, or tauopathies, for dephosphorylation returns the 
protein back to its normal functioning state. One possible rea-
son for this abnormality may be due to a conformational change 
in the MAP tau. This causes it to be a better substrate to be 
phosphorylated or a worse substrate for dephosphorylation. In 
either case, these conformational changes appear to cause the 
pathology of AD (Iqbal, et al., 2005).
AD is typically defined via 3 diverse categories: early-onset AD 
(EOAD), late-onset AD (LOAD), or early-onset familial AD 
(EOFAD). With increasing age as a known risk factor, patients 
who contract the disorder past the age of 65 are said to have 
LOAD which resembles the majority of all AD cases. People who 
are diagnosed with AD before the age of 65 is said to have EOAD 
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which encompasses up to 5 percent of all cases (WebMd, 2014). 
EOFAD is a form of the disorder where the onset of duress 
is under 65 years of age and where the individual has one or 
more of the genes associated with AD. These genes are believed 
to cause the person to attain a genetic disposition towards AD 
(Bird, 1999).
Genetic linkage studies have identified three different genes 
associated with EOFAD. The first gene identified was the APP 
gene (the gene that is responsible for APP production). It is be-
lieved that a missense mutation within this gene is a risk factor 
for EOFAD. Another gene found to be correlated with AD is 
PSEN1. Family studies have shown that mutations in this gene are 
pathogenic. The third gene found injunction with AD is PSEN2. 
Although it is far rarer than the PSEN1 mutation, it is believed 
that mutations in this strand of the gene are a precursor for 
pathogenesis of EOFAD. It is believed that the PSEN1 and PSEN2 
genes are involved with γ-secretase, an enzyme involved with the 
cleavage of APP, and a mutation in these genes cause pathology 
via this pathway. The majority of EOFAD cases (81%) can be ac-
counted for by a mutation in the PSEN1 gene, the second most 
(14%) by a mutation in the APP gene, and the least (6%) associat-
ed with the PSEN2 gene (Ertekin-Taner, 2007). 
Similar to EOFAD, a gene has been found to be associated with 
LOAD. The Apolipoprotein (ApoE) gene codes for a protein that 
transports cholesterol in the bloodstream. It is found as different 
forms named ApoE ε2, ε3, and ε4. The ApoE ε3 form is the most 
common form of the gene while ApoE ε2 and ε4 are less preva-
lent. It is believed that ApoE ε2 reduces the risks of AD and ApoE 
ε4 has the contrasting effect of increasing AD pathogenesis. If 
an individual attains two sets of the ApoE ε4, it greatly increases 
his/her chances of AD. Unlike other known genetic mutations, 
inheriting both sets of the ApoE ε4 gene does not guarantee AD 
pathology (Alzheimer’s Association, 2014). 
While there is no definitive method of ascertaining if an individ-
ual will contract AD, there are several disease-modifying factors 
that decrease or risk factors which increase one’s probabilities of 
pathology. Nam Hu et al (2013) characterizes a list of nutrients 
and their risks towards AD. Antioxidants obtained in an individ-
ual’s diet were shown to reduce the risks of AD. Studies show 
that maintaining a healthy level of vitamin C in a person’s diet can 
have a protective effect towards AD. In regards to metals, Iron is 
believed to be a risk factor for dementia while Zinc is believed 
to be a cause in the delay in AD pathology. In regards to fats and 
carbohydrates, while there is an assumption that these can pose 
as risk factors for AD, not enough reliable evidence is available to 
make a firm conclusion. Hu et al made a graph (figure 2) illustrat-
ing the effects of various everyday foods if whether or not they 
increase or decrease a person’s risk towards AD. 
Various other theories about the pathophysiology of AD con-
tribute to our understanding of the disease. One proposed hy-
pothesis is the degradation of the blood brain barrier (BBB). The 
BBB protects the brain from various pathogens and unwanted 
particles within the bloodstream. The deterioration of the BBB 
can cause various proteins in the blood to enter the cerebral 
spinal fluid and form plaques (Sardi, et al., 2011). Another theory 
involves the metal aluminum. While the correlation is not entirely 
known, it is believed that a high level of aluminum in the brain is 
a cause for AD (Shcherbatykh, 2007). Further research suggests, 
as mentioned by Moulton and Yang (2012), that air pollution too 
plays a role in AD. While the pathogenesis of AD is multifacto-
rial, air pollution can accelerate “age-related oxidative changes 
observed in the brain”, increasing one’s risk of contracting the 
disorder.
Analogous to CJD, patients who suffer from AD share many sim-
ilar phenotypical symptoms. Patients have been known to exhib-
it emotional symptoms such as depression, anxiety, and mood 
swings and cognitive symptoms such as loss of memory, difficulty 
speaking, and difficulty thinking. Additionally, those who contract 
AD are known to have delusions, such as paranoia, change in 
sleeping patterns, and loss of inhibitions. Towards the late pro-
gression of the disorder, important skills such as reading, hobbies, 
and reminiscing are lost (Mayo Clinic Staff, 2014).
Currently, there is no specific diagnostic to confirm the presence 
















Foods and beverages that influence the incidence of AD. Fish, vegetables, 
fruits, coffee, and light-to-moderate alcohol intake are reported to 
reduce AD incidence. Milk and tea are reported to influence cognition, 
but their influence on AD is not clear. (Hu, et al., 2013)
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dementia and often they can determine if it is due to AD. Doctors 
have an arsenal of diagnostic tests that they can perform to assist 
in narrowing the diagnosis. One possible test is a neuropsycho-
logical test where they can identify cognitive changes. Different 
types of dementia can have different cognitive patterns. A blood 
test can be administered to rule out other causes of memory 
loss such as vitamin deficiencies. Frequently, brain imaging is used 
to identify any abnormalities within the brain. An MRI can be 
used to produce a high resolution image of the brain for further 
study. A computerized tomography (CT) scan uses x-rays and a 
computer to generate cross-sectional images of the brain. This 
can help rule out head injuries and tumors. A positron emission 
tomography (PET) scan is used in conjunction with an isotope 
tracer which is injected into an individual. With this machine, a 
doctor can track the movement of this tracer and determine 
which areas of the body are dysfunctional. All of these diagnostics 
aid in the identification of AD; however, similar to CJD, the only 
way to confirm illness is to perform an autopsy and to observe 
plaque buildup within the brain (Mayo Clinic Staff, 2014). 
Pathophysiological Comparison of AD and CJD
AD and CJD are diagnosed via their dissimilar pathological mech-
anism and symptoms. AD is associated with Aβ plaques and Tau 
proteins and CJD with abnormal PrPsc. AD is a slow progressive 
disorder with an extremely high prevalence, afflicting a third of 
octogenarians, while CJD is rapidly progressing with an extreme-
ly low prevalence, afflicting one per million per year. However, no 
matter the dissimilar characteristics between the two disorders, 
there is evidence that there is an analogous mechanism between 
the two. 
It was shown in a study that PrPc prevalence affects the func-
tion of BACE1. BACE1 is a cleaving enzyme which catalyzes the 
cleavage of APP to either Aβ-40 or Aβ-42, two versions of the 
Aβ differing in residue length. A high expression of PrPc reduces 
the severing of the APP into peptide fragments by more than 95. 
This in turn reduces the secretion of Aβ-40 by 92% and Aβ-42 to 
undetectable levels. The support for this conclusion arises from 
the study that showed that reduced PrPc prevalence showed an 
increase in Aβ-40 and Aβ-42 production. This provides strong 
evidence between the correlation between AD and CJD mecha-
nisms (Hooper & Turner, 2008). 
These findings increase the probability that a slight reduction in 
PrPc at a young age could cause an inconsequential accumulation 
of Aβ-40 and Aβ-42 over many years, furthering the accumulation 
of Aβ plaques and the onset of AD. Patients with AD showed 
lower levels of PrPc in their occipital lobes with an increased 
activity of BACE1. Additionally, studies show that a polymorphism 
in codon 129 of the PrPc gene is a risk factor for early-onset AD. 
This polymorphism changes the peptide coded in that location 
to a valine or methionine causing the transconformational alter-
ation to the PrPsc pathogenic form. This is consistent with our 
assumed PrPc-BACE1 relationship. Hooper and Turner (2008) 
suggest that if PrPc affects Aβ production, we can assume that 
the absence of PrPc would lead to early-onset AD. 
If prion proteins regulate Aβ accumulation thus preventing AD, 
does Aβ regulate and/or prevent prion pathology? In an experi-
ment involving mice infected with scrapie, a form of prion disease 
in animals, it was found that in the terminal stages of the disease 
there was a considerable increase in the concentration of Aβ. 
Hooper and Turner comments on this that, “[i]nterestingly, the 
amounts of Aβ peptides were high in scrapie-infected mice, with 
a shorter disease incubation time raising the possibility that the 
higher levels of Aβ might exacerbate the disease process.”  If this 
theory is correct that high Aβ levels contribute to the rate of 
prion pathology, then this can be used as a way to slow down 
the progression of these ailments. However, they point out that 
we cannot rule out that the increased levels of Aβ are perhaps 
a result of the scrapie pathology, as stated before, and that fur-
ther study is necessary to confirm this hypothesis (Hooper & 
Turner, 2008). Furthermore, Debatin et al (2008) point out that 
the increased levels of Aβ could be the result of the saturation of 
clearance mechanisms; since the body is preoccupied with PrPsc 
maintenance, the same mechanism that also deals with Aβ accu-
mulation becomes saturated leading to a buildup of the AD asso-
ciated protein. This theory is supported by evidence that suggests 
a common pathway for protein degradation of PrPsc and Aβ.
Alternatively, there are those that argue that overexpression of 
PrPc increase Aβ plaque production. Lara Ordonez-Gutierrez et 
al (2013) disregard the evidence that suggest that PrPc directly in-
hibits Aβ production by altering the activity of BACE1. They state 
that most of these tests were performed in cell cultures while 
studies involving older animals showed no change in the expres-
sion of BACE1 in regards to PrPc concentrations. Furthermore, 
in vivo experimentation conducted by Ordonez-Gutierrez et al 
(2013) discovered that older animals that expressed a high level 
of PrPc expression also illustrated a high level of Aβ deposits 
with no significant consequence on BACE1 levels. They speculate 
that since BACE1 levels stay the same while Aβ deposit levels 
increase, perhaps this surge in plaque formation is a result of 
increased protein degradation and/or production via an alternate 
pathway involving PrPc.
Its been suggested that a divergent reasoning for the accumu-
lation of Aβ deposits in patients with a high PrPc expression. 
They explain, given the fact an unaltered expression of PrPc is 
observed during the pathology of prion disease, it is unlikely pri-
ons are the cause for Aβ accumulation in specific sCJD patients. 
Being that the aggregation of misprocessed proteins is caused by 
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the differences between de novo generation and its elimination, it 
is a possibility that the increased levels of Aβ deposits in sCJD are 
a result of a saturation of common clearance mechanisms. This 
is validated by studies that show a similar clearance mechanism 
is in place for both PrPsc and Aβ. Furthermore, in a group study 
of sCJD patients, individuals who exhibited high levels of Aβ-42 
showed little deposits of PrPsc while individuals with high levels 
of PrPsc had low amounts of Aβ-42. The correlation between 
Aβ-42 and PrPsc concentrations clearly indicates a shared mech-
anism between the two (Debatin, et al., 2008).
There are also reports discussing a few intriguing similarities 
between AD and CJD. Both AD and CJD are characterized by 
their peptide aggregations resulting in plaques; Aβ in AD and 
PrPsc in CJD. Additionally, the authors explain how AD and CJD 
can coexist in the same individual and that the Aβ and PrPsc 
plaques in sporadic AD and sCJD share a similar spatial distri-
bution throughout the brain, “suggesting a consistent pattern of 
cortical degradation of the two disorders (Armstrong, Lantos, & 
Cairns, 2005).” With all of these similarities, including the ones 
mentioned earlier, it is hard to deny the correlation between 
these two neurodegenerative diseases.
Possible Treatments for CJD
In persons with vCJD, it was observed that when ingested orally, 
infectious prions aggregated towards gut-assisted lymphatic tis-
sue and the spleen (Cashman & Caughey, 2004). From this loca-
tion, the prions are transported via splanchnic 
innervation to the spinal cord and brain (Figure 3). Cashman and 
Caughey point out that replication of these prions occur in loca-
tions accessible to immunotherapy and antibody neutralization. 
Due to the pathogenic pathway observed in vCJD, it is a possibil-
ity to artificially induce an autoimmune response against prions 
affecting its replication.  This can effectively slow down or block 
pathogenesis of the disease. It has been illustrated in studies that 
Possible spread of scrapie infectivity from the gut lumen to the nervous system following oral infection (route indicated by dotted line)� Soon after ingestion, 
the abnormal prion isoform (PrPSc) is detected readily within Peyer’s patches on follicular dendritic cells (FDCs), within macrophages, within cells with 
morphology consistent with that of M cells and within ganglia of the enteric nervous system (ENS)� These observations indicate that, following uptake of 
scrapie infectivity from the gut lumen, infectivity accumulates on FDCs in Peyer’s patches and subsequently spreads via the ENS to the central nervous 


















Ganglia of EDSAgent spread
Dendritic cell
73
Creutzfeldt - Jakob and Alzheimer’s Diseases: Overlap of Treatment Methods?
antibodies targeted against PrPc, cleared cells that were scra-
pie-infected with PrPsc in vitro. However, in vivo, antibodies tar-
geted against normal PrPc can have adverse effects since these 
cells in their non-pathogenic configuration are detrimental to 
normal neurological function. The autoimmune response to PrPc 
can prompt complement-dependent lysis in many cells disrupting 
normal function leading to apoptosis in the brain. It is entirely 
possible for an induced antibody response to reduce the immu-
nological tolerance of PrPc with the subsequent induction of an 
autoimmune disease (Cashman & Caughey, 2004). 
Often when a protein misfolds causing pathology, a sidechain 
of peptides that originally was sequestered within the molecule 
becomes exposed providing a means of distinguishing between 
pathogenic and non-pathogenic conformational isotopes. This 
specificity can aid in devising a means of targeting PrPsc alone 
without affecting the normal PrPc. The therapeutic potential of 
this approach is immense with the benefit of leaving non-patho-
genic proteins unharmed (Paramithiotis, et al., 2003).
There are several chemical inhibitors of CJD progression in vitro. 
Cyclic tetrapyrroles have been shown to slow the progression of 
scrapie in mice; however, this was only if treatment began imme-
diately after infection due to its inability to cross the BBB. Other 
tetrapyrroles that do cross the BBB could prove to be efficacious 
further in the stages of infection. It is believed that cyclic tet-
rapyrroles inhibit PrPsc by direct interaction with the protein. 
Polyene antibiotics and dimethlysulphoxide are also thought to 
inhibit PrPsc pathology. Polyene antibiotics target prions while 
dimethlysulphoxide helps reduce accumulations and excretion of 
PrPsc. Unfortunately, no chemotherapeutic drug has been shown 
to significantly alleviate the pathology of CJD once clinical symp-
toms are present (Cashman & Caughey, 2004).
Several other therapies have been suggested for CJD treatment. 
One is through gene therapy via a lentiviral vector-mediated 
RNA interference (RNAi). A lentivirus is a genus of viruses that 
can be modified to implement specific genes within a host’s ge-
nome or silence others. This is achieved through short hairpin 
RNAs (shRNAs) that can silence select genes. A study conducted 
with scrapie-infected neuronal cells that involved shRNAs that 
suppressed the PrPc gene, PRNP, showed an efficient suppression 
of PrPsc aggregation. Mice infected with lentivirues with shRNAs 
showed a reduced expression of PrPc and an extended lifespan 
of those infected with scrapie. Although further testing needs to 
be done, a lentiviral vector-mediated RNAi appears to be a valid 
approach for the treatment of CJD (Pfeifer, et al., 2006). However, 
reducing PrPc expression may hinder CJD pathogenesis but it 
may also contribute to various adverse effects. additional re-
search will need to be conducted to attain a viable solution to 
these concerns.
Another suggested therapy is by the use of antihistamines, specif-
ically astemizole. Experiments involving astemizole indicated that 
it prolonged the lifespan of scrapie-infected mice. Additionally, 
astemizole has the capabilities of crossing the BBB making it a 
favorable drug for the treatment of CJD. Except for a rare case of 
heart arrhythmia, astemizole is an over-the-counter drug that is 
relatively safe in recommended doses. It is theorized that astem-
izole’s antiprion properties arises from its activity on autophagy, 
which is the degradation and recycling of cells and proteins. It 
is suggested that individuals containing mutations in the PRNP 
gene and who are genetically susceptible to CJD should take as-
temizole regularly as a preventative measure against disease. The 
effects of astemizole on autophagy could provide new methods 
for treating other neurodegenerative diseases (Karapetyan, et al., 
2013).
CJD treatments vs AD pathology
Can several potential treatments for CJD be administered or 
modified to treat AD? AD is associated with the accumulation of 
abnormal proteins (Aβ and/or Tau proteins). It is possible to tar-
get these molecules via an induced autoimmune response such 
as that observed in CJD treatments (Cashman & Caughey, 2004). 
However, this can initiate a negative cascade in which the body 
targets normal functioning Aβ or Tau proteins resulting in cell 
lysis and the reduced immunological tolerance towards normal 
cells causing autoimmune disease. 
Abnormal proteins are often accompanied by the exposure of a 
previously sequestered side chain. This side chain can be used to 
target pathogenic proteins alone without interfering with nor-
mal function. These findings can be applied to AD in treating Aβ 
and Tau fibril accumulations. Although further experimentation is 
needed to produce a safe autoimmune induced treatment, this 
can be a viable method to combat AD pathology (Paramithiotis, 
et al., 2003).
Lentivector-mediated RNAi can be used to treat AD as well. 
ShRNAs that repress specific gene expression could be used to 
suppress a faulty gene that causes pathology. For instance, if an 
individual has two genes coding for a molecule involved in the 
pathogenic AD pathway with one of the genes corrupted and the 
other in its normal function, shRNAs can be utilized to silence 
the faulty gene’s expression without affecting the normal one. 
However, Lentivector-mediated RNAis can suppress the function 
of both normal and faulty genes causing unwanted adverse effects 
(Pfeifer, et al., 2006). This prototype treatment for CJD can ulti-
mately be utilized to treat other disorders such as AD. 
Direct modification of PrPsc/PrPc levels is another option for 
AD treatment. With a theorized mechanism correlation between 
PrPc and Aβ proteins, it is possible to indirectly treat AD by 
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inducing prion production. For instance, Hooper and Turner be-
lieve that PrPc regulates Aβ levels by inhibiting enzyme catalyzed 
cleavage of APP to Aβ-40 and Aβ-42. The greater the PrPc levels, 
the lower the levels of Aβ in the body. If a patient has AD due 
to high levels of Aβ, according to Hooper and Turner (2008), it 
should be possible to reduce these levels by increasing expres-
sion of PrPc production (see figure 4). Ordonez-Gutierrez et al 
(2013) argue that increased levels of PrPc increase Aβ plaque 
formation. This suggests that reducing PrPc concentrations is the 
viable method in treating Aβ aggregations in AD. More data has 
to be obtained to procure the exact mechanism between PrPc 
and Aβ. It seems that both Hooper and Turner and Ordonez-
Guiterrez et al agree that a related mechanism exists between 
the two proteins, it is the effect one has on the either that is 
in question. Either way, understanding how these two molecules 
interact can be important in treating either of these two neu-
rodegenerative disorders. Prion diseases can offer scientists a 
prototype on the processes of other neurological disorders such 
as AD (Cashman & Caughey, 2004).
Possible treatments for AD
Currently, AD patients are treated with two different types of 
drugs, either acetylcholinesterase inhibitors or memantine. 
Acetylcholinesterase inhibitors act by increasing cell-to-cell 
communication chemical levels that were diminished during AD 
onset. This is accomplished by inhibiting enzymes that facilitate 
the breakdown of acetylcholine, a neurotransmitter found with-
in the brain. Progression of symptoms is usually maintained for 
a time before AD pathology continues to worsen. Memantine 
works via a different pathway within the brain, slowing the de-
velopment of symptoms relating to AD. The mode of action for 
memantine is to target and inhibit NMDA receptors which has 
shown to improve cognitive function compared to a placebo. 
Unfortunately, medication only forestalls pathology since there is 
no cure for AD (Gotz, Ittner, & Ittner, 2012) (Eubanks, et al., 2006) 
(Mayo Clinic Staff, 2014). 
Research into the immunization against Aβ showed promising 
results. Mice immunized with Aβ-42 showed reduced Aβ burden 
and preserved cognitive function. In an interrupted clinical trial, 
patients who were injected with one, two, or three immuniza-
tions of Aβ-42 showed decreased levels of tau proteins with 
postmortem reports of diminished Aβ in the neocortex. The trial 
was interrupted because 6% of the patients developed meningo-
encephalitis (Gilman, et al., 2005). Using natural anti- Aβ antibod-
ies derived from healthy humans may provide a better method 
in reducing adverse effects such as encephalitis in patients (Sardi, 
et al., 2011). Although the clinical trial was suspended, immuno-
therapy seems to be a viable method in treating AD (Gilman, et 
al., 2005). 
In a recent pharmaceutical study, a monoclonal antibody aimed 
at Aβ named Bapineuzumab was intravenously administered for 
78 weeks. It was found that there was a diminished phosphory-
lated tau along with a reduced accumulation of Aβ in the brain 
of AD individuals carrying the pro-pathological gene, ApoE ε4. 
These findings show promise in the treatment of AD through re-
ductions of plaque buildup. Interestingly, these reductions of the 
disease-inducing molecules were not able to forestall the rate of 
pathological progression in the disorder. One suggested hypoth-
esis is that Bapineuzumab was administered too far along in the 
AD pathology. To remedy this concern, the drug would have to 
be administered before the appearance of clinical symptoms. This 
poses an issue since it is extremely difficult to diagnose a patient 
before symptoms appear; however, it may be able aid those who 
are high risk for AD. Another hypothesis is the actual pharma-
ceutical mechanism of the drug. As of yet, Bapineuzumab does 
not target phosphorylated tau that aggregated into neurofibril-
lary tangles, another hallmark of AD (Cedernaes, et al., 2014). 
While further study is needed to improve the efficaciousness of 
antibodies against AD, immunotherapies are strong contenders in 
discovering a feasible treatment for neurodegenerative diseases. 
Non-steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to be a preventative measure for AD. There are reports 
that suggest that BBB degradation plays a central role in AD. 
As the BBB degrades, many previously unwanted molecules 
cross into the fluid surrounding the brain possibly eliciting a re-
sponse of inflammation. Inflammation can further increase the 
The role of the prion protein in Alzheimer’s disease prevention: In the amyloid 
cascade hypothesis of AD, a genetic mutation (for example, in the genes 
encoding APP or the presenilins), ageing or some other environmental trigger 
(e�g� oxidative stress) causes an accumulation of the neurotoxic Ab peptide, 
which aggregates to form the characteristic amyloid (senile) plaques found 
post-mortem in the brains of AD patients� Through mechanisms that are 
poorly understood, the increased levels of Ab peptides, particularly oligomeric 
and fibrillar forms, cause neuronal cell death and dementia. The normal 
cellular form of the prion protein, through inhibiting the production of the 
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permeability of the BBB allowing circulating Aβ to enter the brain 
where it can start a degenerative and inflammatory process. 
NSAIDs are drugs that reduce pro-inflammatory responses in 
the body. Studies have shown that patients who were medicated 
with NSAIDs over a long period of time exhibited a reduced 
incidence of AD. This indicates the presence of pro-inflammatory 
molecules in the pathology of AD (Sardi, et al., 2011).
Many therapies for AD focus on ameliorating Aβ levels in the 
brain without much focus on tau proteins concentrations. 
Treatments aimed at pathogenic tau proteins produced reason-
able results. Abnormal tau proteins are phosphorylated versions 
of the normal tau form. One method of treatment is to inhibit 
this phosphorylation. Administered lithium chloride inhibited gly-
cogen synthase kinase-3, an enzyme that catalyzes the transfer 
of a phosphate group onto other molecules, and reduces the 
levels of hyperphosphorylated tau, insoluble tau, and behavioral 
impairment in various mice models. Inhibition of other kinases 
also showed promising results. Furthermore, immunization with a 
tau phospho-peptide prevented pathology in tau transgenic mod-
els with no apparent adverse effects (Gotz, et al,, 2012). With the 
promise of tau directed therapies, it is worthwhile to formulate 
treatments involving both Aβ in conjunction with tau proteins. 
The active component of marijuana, ∆9-tetrahydrocannabinol 
(THC), appears to also be an efficacious and viable method in 
the treatment of AD. THC competitively inhibits the enzymat-
ic protein acetylcholinesterase which catalyses the breakdown 
of acetylcholine. It is believed that acetylcholinesterase is a key 
component in the pathological progression of AD by inducing 
Aβ plaque formation. THC effectively inhibits this enzyme, re-
ducing the degradation of acetylcholine transmitters in the brain 
while simultaneously diminishing Aβ plaque formation. This treats 
both the progression and the symptoms of the disease. THC is 
a superior inhibitor of acetylcholinesterase as opposed to other 
acetylcholinesterase inhibiters that are currently used to treat 
AD. Additionally, THC appeared more effective with only half the 
dosage compared to these other medications.  (Eubanks, et al., 
2006). 
The treatment of metabolic deficiency is another suggested al-
ternative in treating AD. An abnormality in the energy metab-
olism, calcium metabolism, or free radical pathways showed to 
contribute to deficiency within the other two metabolic routes 
creating a “mitochondrial spiral”. This spiral forms a negative cas-
cade effect where the defects of one metabolic pathway continue 
to degrade other pathways which in turn further damage the 
original faulty pathway (see figure 5).  It is thought that mito-
chondrial spiral causes abnormities in the metabolism of the APP 
and the segments of Aβ it produces. It may also be a proximate 
reason for clinical debilities found in AD. Ameliorating the spiral 
may be an alternative route in AD treatment. Studies involving 
an induced increase in metabolic activity by administering a con-
coction of glucose and several Krebs cycle intermediates into 
patients showed an increase in cognitive function with less neu-
rodegeneration. Improving a deficient mitochondrial spiral may 
prove to be effective in treating AD (Blass, 2001).
AD treatments vs CJD pathology
With AD and CJD sharing many pathological pathways, it seems it 
may be possible to treat CJD via techniques previously reserved 
for AD. Acetylcholinesterase inhibitors that reduce the enzymat-
ic degradation of acetylcholine perhaps can be used to alleviate 
symptoms of dementia found in patients with CJD (Cummings, 
2000). With the increased levels of the neurotransmitter ace-
tylcholine in vivo, there can be an increased level of cell-to-cell 
communications within the brain possibly easing several cognitive 
symptoms. However, inhibition of this enzyme is most likely not a 
viable method of treatment for there is little research conducted 
on the effects of acetylcholinesterase inhibitors on CJD. There is 
some evidence that memamtine, another drug used to treat AD, 
has some inhibitory effects towards PrPsc (Muller, et al., 1993).
Immunizations for CJD have been thought of as a method of 
treatment as well. Similar to AD, antibodies targeted against pro-
teins associated with CJD have showed some promising results. 
However, being that adverse effects were found with immuniza-
tions, research has to be done before it is safe for public use as 
a treatment for CJD (Cashman & Caughey, 2004). NSIADs have 
been suggested as a treatment for CJD. Inflammation has been 
associated with both AD and CJD. In contrast to AD, there is 
little data available on the effectiveness of NSAIDs on CJD. In 
vivo studies showed that NSAIDs may have some effect on prion 
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disappointing results. It is possible that the NSAIDs were given 
too late in the disease pathogenesis. Further study is needed to 
determine if antiinflammatory drugs are a suitable treatment for 
CJD (Eikelenboom, et al., 2002). 
Treatment of the “mitochondrial spiral” may play a role with indi-
viduals with CJD. In regards to AD, it was found that a deficiency 
in one of three different metabolic pathways can cause deficits 
in the other two creating a mitochondrial spiral. Attempts to 
alleviate the stress on this spiral showed to improve cognitive 
symptoms in patients (Blass, 2001). In CJD, some studies show 
oxidative abnormalities plays a role in pathogenesis (Petersen, et 
al.). This can cause defects in one of the three metabolic pathways 
mentioned earlier. Alleviating these deficiencies may be a viable 
venue of treatment. It should be mentioned that other studies 
found no role of oxidative stress in CJD (Bleich, et al., 2000). 
Further study is needed on the topic to fully understand the 
effects of the mitochondrial spiral on disease pathogenesis.
It was suggested that it is possible that Aβ contributes to CJD 
pathology. It has been hypothesized that Aβ exacerbated the dis-
ease process by possibly accelerating the pathology (Hooper & 
Turner, 2008). If this hypothesis proved to be correct, any treat-
ment formulated towards AD can in turn be prescribed for the 
mitigation and delaying of symptoms in CJD. Additionally, it was 
found that the other protein linked with AD, tau proteins, were 
associated with prion pathology (Han, et al., 2006). As additional 
experimentation is required to determine the exact impact of 
one protein on the other, treatments made to diminish tau pa-
thology may ameliorate symptoms of CJD. These hypothesized 
venues of remedy will not cure prion pathology but can most 
likely hinder CJD neurodegenerative impacts on the brain. The 
correlation between these two diseases is too strong to suggest 
otherwise. Furthering research into understanding CJD is a via-
ble method of ascertaining a feasible treatment for the growing 
epidemic that is AD.
Conclusion
AD and CJD are both neurodegenerative disorders that share a 
common pathophysiological mechanism. PrPc and Aβ, proteins as-
sociated with pathology in CJD and AD respectively, are believed 
to interact with each other. There is a slight debate whether they 
interact directly by contact or indirectly by affecting enzymatic 
proteins, such as BACE1. Additionally, there is an argument how 
they influence each other in regards to inhibiting/promoting pa-
thology; for example, does PrPc induce or inhibit Aβ aggregations 
that cause pathology? Either way, there is a strong correlation of 
pathologies that most scientists agree with. It is this connection 
that helped researchers discover new and creative treatments 
for AD and CJD. Treatments that were previously reserved for 
either disease are now being tested against the other. This is 
enhancing the understanding of the mechanisms of each ailment, 
bringing researchers one step closer to discovering a cure for 
both neurodegenerative diseases. Perhaps, discovering the means 
of pathologies for AD and CJD will lead to cures for many other 
forms of dementia. 
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